リツキシマブの投与によって生じた口腔・上部消化管潰瘍の1例

  • 青田 桂子
    徳島大学大学院ヘルスバイオサイエンス研究部口腔内科学分野
  • 高野 栄之
    徳島大学大学院ヘルスバイオサイエンス研究部口腔内科学分野
  • 細川 浩良
    徳島大学大学院ヘルスバイオサイエンス研究部口腔内科学分野
  • 可児 耕一
    徳島大学大学院ヘルスバイオサイエンス研究部口腔内科学分野
  • 山村 佳子
    徳島大学大学院ヘルスバイオサイエンス研究部口腔内科学分野
  • 東 雅之
    徳島大学大学院ヘルスバイオサイエンス研究部口腔内科学分野

書誌事項

タイトル別名
  • A case of oral, pharyngeal, esophageal, and gastric ulcer in a patient with primary macroglobulinemia showing remission by treatment with rituximab
  • リツキシマブ ノ トウヨ ニ ヨッテ ショウジタ コウコウ ・ ジョウブ ショウカカン カイヨウ ノ 1レイ

この論文をさがす

抄録

We report a case of oral, pharyngeal, esophageal, and gastric ulcer in patient with Waldenström macroglobulinemia( WM) in a 64-year-old woman in whom remission was induced by the administration of rituximab 6 months previously. She consulted our hospital because of ulcer formation in the right side of the floor of the mouth. A biopsy specimen showed inflammation. Five days later, the patient had a fever of 39℃, and the ulcer extended to the tongue and the left side of the floor of the mouth. Blood examination demonstrated delayed-onset neutropenia after treatment with rituximab. Although the symptoms were improved by antibacterial therapy, the ulcer with fever recurred 4 months later. The ulcer was observed not only in the mouth, but also in the pharynx, esophagus, and stomach. Since neutropenia continued and CD19, a monoclonal B cell antibody, was 0% , the patient received both G-CSF and an antibacterial drug. In addition, a proton pump inhibitor was given. These treatments led to improvement of the ulcer. <BR>The fact that severe delayed-onset neutropenia was induced by rituximab in the patient suggested that infection with endogenous microbial flora caused the ulcer in the mouth, pharynx, esophagus, and stomach. On the other hand, in the stomach with few endogenous microbial flora, the lack of the regulatory B cells apparently inhibited IL-10 production. Consequently, the activation of macrophages and neutrophils may have caused the ulcer formation.

収録刊行物

参考文献 (9)*注記

もっと見る

関連プロジェクト

もっと見る

詳細情報

問題の指摘

ページトップへ